Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.50 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.45 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501782 | 1.00 | KCNN4 (0.50) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL6335614 | 0.98 | KCNN4 (0.49) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL30501842 | 0.84 | CES2 (0.44) | KCNN4KCNE1KCNQ1CES2CES1 | |
| SCHEMBL1626654 | 0.84 | CES2 (0.44) | KCNN4KCNE1KCNQ1CES2CES1 | |
| SCHEMBL12841736 | 0.83 | KCNN4 (0.46) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL31560841 | 0.82 | KCNN4 (0.49) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL3861565 | 0.82 | KCNN4 (0.58) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL1822203 | 0.82 | KCNN4 (0.49) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL31691802 | 0.82 | KCNN4 (0.58) | KCNN4KCNE1KCNQ1HDAC3HDAC1 | |
| SCHEMBL714233 | 0.80 | KCNN4 (0.51) | KCNN4KCNE1KCNQ1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357610-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230414566-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-12-28 | — | — | US | disclosed |
| WO-2023229378-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2023-11-30 | — | — | WO | disclosed |
| US-11806333-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023117681-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| EP-3728263-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN ELECTRONIC DEVICES. | MERCK PATENT GMBH (DE) | 2022-06-15 | — | — | EP | disclosed |
| US-20210363159-A1 | HETEROCYCLIC COMPOUND FOR USE IN ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2021-11-25 | — | — | US | disclosed |
| US-20200360342-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-11-19 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| EP-2111399-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008076427-A2 | NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| CN-1972916-A | Cinnamide compounds | EISAI R&D MAN CO LTD (JP) | 2007-05-30 | — | — | CN | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360342-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885KCNE1 553/4885KCNQ1 595/4885 |
| US-20090093483-A1 | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | EGLN2, EGLN3, HIF1AN | KCNN4 4743/4885KCNE1 4088/4885KCNQ1 4354/4885 |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | KCNN4 3024/4885KCNE1 4038/4885KCNQ1 4482/4885 |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | KCNN4 3497/4885KCNE1 2394/4885KCNQ1 2061/4885 |
| US-12357610-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885KCNE1 553/4885KCNQ1 595/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | KCNN4 991/4885KCNE1 1859/4885KCNQ1 3169/4885 |
| US-20210363159-A1 | HETEROCYCLIC COMPOUND FOR USE IN ELECTRONIC DEVICES | DDT, NQO1, CYP2E1 | KCNN4 562/4885KCNE1 47/4885KCNQ1 33/4885 |
| US-20230414566-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885KCNE1 553/4885KCNQ1 595/4885 |
| US-11806333-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885KCNE1 553/4885KCNQ1 595/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | KCNN4 1438/4885KCNE1 3828/4885KCNQ1 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.